Visceral steatosis, congenital

Summary

Visceral steatosis, congenital (MONDO:0009220) is a disease and 1 clinical trial. A subtype of fatty liver disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	visceral steatosis, congenital
Mondo ID	MONDO:0009220
MeSH	C536351
OMIM	228100
SNOMED CT	270881008
UMLS	C0341447
MedGen	90962
GARD	0008514
Is cancer (heuristic)	no

Also known as: fatal neonatal hepatic steatosis · visceral steatosis · visceral steatosis, congenital

Disease family

This is a subtype of fatty liver disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › fatty liver disease › visceral steatosis, congenital

Related subtypes (3): metabolic dysfunction-associated steatotic liver disease, alcoholic fatty liver disease, metabolic dysfunction and alcohol associated liver disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05359471	Not specified	UNKNOWN	Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD